NCT05032001

ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Metabolic Research Unit · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. Quantification of visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial tomography. Different available oral antidiabetics cause weight loss and total body fat (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2 inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with BIA in T2D patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.

Conditions

• Abdominal Obesity
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Biguanide, DPP4 inhibitors, SGLT2 inhibitors	Oral antidiabetic treatment during twelve weeks

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-08-01
• Completion: 2022-08-01
• First posted: 2021-09-02
• Last updated: 2021-09-09

Locations

1 site across 1 country: Mexico